Literature DB >> 20086038

Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions.

L T May1, S J Briddon, S J Hill.   

Abstract

Allosteric binding sites on the adenosine receptor family represent potential therapeutic targets for a number of conditions involving metabolic stress. This study has identified Brilliant Black BN as a novel allosteric modulator of the adenosine A(1) and A(3) receptors. In addition to being a food dye and pharmaceutical excipient, Brilliant Black BN is commonly used within calcium mobilization assays to quench extracellular fluorescence. Brilliant Black BN (5-500 microM) had no significant effect on the calcium mobilization stimulated by the nonselective adenosine receptor agonist 5'-(N-ethylcarboxamido)adenosine in Chinese hamster ovary cells stably transfected with the human adenosine A(1) or A(3) receptor. Likewise, calcium mobilization and radioligand binding assays found that Brilliant Black BN (5-500 microM) did not significantly influence the antagonism mediated by 8-cyclopentyl-1,3-dipropylxanthine (100 nM) at the A(1) receptor. In contrast, the affinity of N-[9-chloro-2-(2-furanyl)[1,2,4]-triazolo[1,5-c]quinazolin-5-yl]benzene acetamide (MRS1220) at the A(3) receptor and xanthine amine congener (XAC) and XAC-X-BY630 at the A(1) and A(3) receptors was significantly decreased in the presence of 500 muM Brilliant Black BN. A reduction in XAC potency at the A(1) and A(3) receptor was achieved within 1 min of Brilliant Black BN addition, despite receptors having been pre-equilibrated with antagonist. Dissociation kinetics of the fluorescent XAC derivative, XAC-X-BY630, revealed that the decrease in affinity is probably due to a significant increase in dissociation rate of the antagonist in the presence of Brilliant Black BN. Taken together, these results suggest that Brilliant Black BN can act allosterically to modify ligand affinity at A(1) and A(3) receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086038      PMCID: PMC2845936          DOI: 10.1124/mol.109.063065

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  39 in total

1.  Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue.

Authors:  M F Jarvis; C T Wismer; E Schweitzer; H Yu; K J Lynch; E C Burgard; E A Kowaluk
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 2.  P2 purinergic receptors: modulation of cell function and therapeutic potential.

Authors:  G Burnstock; M Williams
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

3.  Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives.

Authors:  Z G Gao; J E Van Muijlwijk-Koezen; A Chen; C E Müller; A P Ijzerman; K A Jacobson
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

Review 4.  Regulation of phosphoinositide-specific phospholipase C.

Authors:  S G Rhee
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

5.  2-Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A(1) adenosine receptors.

Authors:  C Elisabet Tranberg; Andrea Zickgraf; Brian N Giunta; Henning Luetjens; Heidi Figler; Lauren J Murphree; Ruediger Falke; Holger Fleischer; Joel Linden; Peter J Scammells; Ray A Olsson
Journal:  J Med Chem       Date:  2002-01-17       Impact factor: 7.446

6.  Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury.

Authors:  Weiguo Peng; Maria L Cotrina; Xiaoning Han; Hongmei Yu; Lane Bekar; Livnat Blum; Takahiro Takano; Guo-Feng Tian; Steven A Goldman; Maiken Nedergaard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

7.  Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor.

Authors:  P G Baraldi; A N Zaid; I Lampronti; F Fruttarolo; M G Pavani; M A Tabrizi; J C Shryock; E Leung; R Romagnoli
Journal:  Bioorg Med Chem Lett       Date:  2000-09-04       Impact factor: 2.823

8.  Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity.

Authors:  Y Cordeaux; S J Briddon; A E Megson; J McDonnell; J M Dickenson; S J Hill
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

Review 9.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

10.  Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands.

Authors:  Jillian G Baker; Richard Middleton; Luke Adams; Lauren T May; Stephen J Briddon; Barrie Kellam; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2010-01-26       Impact factor: 8.739

View more
  12 in total

1.  Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists.

Authors:  Jinha Yu; Philip Mannes; Young-Hwan Jung; Antonella Ciancetta; Amelia Bitant; David I Lieberman; Sami Khaznadar; John A Auchampach; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2018-10-18       Impact factor: 3.597

2.  Synthesis of BODIPY derivatives substituted with various bioconjugatable linker groups: a construction kit for fluorescent labeling of receptor ligands.

Authors:  Fabian Heisig; Sabrina Gollos; Sven J Freudenthal; Ali El-Tayeb; Jamshed Iqbal; Christa E Müller
Journal:  J Fluoresc       Date:  2013-09-20       Impact factor: 2.217

Review 3.  New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism.

Authors:  Elizabeth A Vecchio; Jo-Anne Baltos; Anh T N Nguyen; Arthur Christopoulos; Paul J White; Lauren T May
Journal:  Br J Pharmacol       Date:  2018-06-21       Impact factor: 8.739

Review 4.  Allosteric modulation of purine and pyrimidine receptors.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Anikó Göblyös; Adriaan P Ijzerman
Journal:  Adv Pharmacol       Date:  2011

5.  Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics.

Authors:  Lauren T May; Lloyd J Bridge; Leigh A Stoddart; Stephen J Briddon; Stephen J Hill
Journal:  FASEB J       Date:  2011-06-29       Impact factor: 5.191

6.  Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.

Authors:  Jillian G Baker; Luke A Adams; Karolina Salchow; Shailesh N Mistry; Richard J Middleton; Stephen J Hill; Barrie Kellam
Journal:  J Med Chem       Date:  2011-09-16       Impact factor: 7.446

7.  Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation.

Authors:  Karolina Gherbi; Lauren T May; Jillian G Baker; Stephen J Briddon; Stephen J Hill
Journal:  FASEB J       Date:  2015-04-02       Impact factor: 5.191

Review 8.  Biophysical Detection of Diversity and Bias in GPCR Function.

Authors:  Werner C Jaeger; Stephen P Armstrong; Stephen J Hill; Kevin D G Pfleger
Journal:  Front Endocrinol (Lausanne)       Date:  2014-03-05       Impact factor: 5.555

Review 9.  Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization.

Authors:  Stephen J Hill; Lauren T May; Barrie Kellam; Jeanette Woolard
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

10.  Kinetic analysis of antagonist-occupied adenosine-A3 receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism.

Authors:  Ross Corriden; Laura E Kilpatrick; Barrie Kellam; Stephen J Briddon; Stephen J Hill
Journal:  FASEB J       Date:  2014-06-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.